Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients (FUMANCE)
Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients
Sponsor: Clinical Research Technology S.r.l.
A PHASE3 clinical study on Metastatic Breast Cancer, this trial is ongoing. The trial is conducted by Clinical Research Technology S.r.l. and has accumulated 7 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Research Technology S.r.l.
- Consorzio Oncotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ascoli Piceno, Italy , Avezzano, Italy , Fabriano, Italy , Faenza, Italy , Foggia, Italy , Latina, Italy , Lecce, Italy , Lido di Camaiore, Italy , Lucca, Italy , Mecerata, Italy and 8 more locations